(Q46796258)

25 December 2017

title

The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer (English)

1 reference

25 December 2017

1 reference

Y Kaida

1

1 reference

25 December 2017

N Inui

2

1 reference

25 December 2017

T Suda

3

1 reference

25 December 2017

H Nakamura

4

1 reference

25 December 2017

H Watanabe

5

1 reference

25 December 2017

K Chida

6

1 reference

25 December 2017

language of work or name

English

0 references

publication date

23 January 2008

1 reference

25 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

25 December 2017

volume

83

1 reference

25 December 2017

issue

4

1 reference

25 December 2017

page(s)

589-594

1 reference

25 December 2017

Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

The contribution of cytochrome P450 to the metabolism of tegafur in human liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

A novel single nucleotide polymorphism altering stability and activity of CYP2a6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization m

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100484

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100484

1 reference

25 December 2017

1 reference

25 December 2017